Literature DB >> 21924539

[Lymphangioleiomyomatosis: new therapeutic approaches].

Alvaro Casanova, Julio Ancochea.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21924539     DOI: 10.1016/j.arbres.2011.06.008

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


× No keyword cloud information.
  6 in total

1.  Lymphangioleiomyomatosis: current and future.

Authors:  Maria Mavroudi; Paul Zarogoulidis; Nikolaos Katsikogiannis; Kosmas Tsakiridis; Haidong Huang; Antonios Sakkas; Anastasios Kallianos; Aggeliki Rapti; Eirini Sarika; Ilias Karapantzos; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

2.  Solitary extrapulmonary lymphangioleiomyomatosis of the liver: A case report and literature review.

Authors:  Weiwei Fu; Yujun Li; Hong Li; Ping Yang; Xiaoming Xing
Journal:  Exp Ther Med       Date:  2016-07-05       Impact factor: 2.447

3.  Surgical treatment of chylothorax caused by lymphangioleiomyomatosis.

Authors:  Mingliang Liu; Bingqun Wu; Yong Cui; Dong Chang; Shuhong Zhang; Min Gong
Journal:  J Thorac Dis       Date:  2014-02       Impact factor: 2.895

4.  Sporadic lymphangioleiomyomatosis with bloody sputum as an initial symptom: A case report and review of the literature.

Authors:  Kai Wu; Hui-Yu Lu
Journal:  Exp Ther Med       Date:  2015-03-31       Impact factor: 2.447

5.  Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

Authors:  Xiaoxiao Gu; Jane J Yu; Didem Ilter; Nickolas Blenis; Elizabeth Petri Henske; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-27       Impact factor: 11.205

6.  Hormonal manipulation with letrozole in the treatment of metastatic malignant pecoma.

Authors:  P Le; A Garg; G Brandao; A Abu-Sanad; L Panasci
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.